Drug
Kremezin
Kremezin is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_4
3
75%
Ph phase_1
1
25%
Phase Distribution
1
Early Stage
0
Mid Stage
3
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 4Post-market surveillance
3(75.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(3)
Other(1)
Detailed Status
Completed3
unknown1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 11 (25.0%)
Phase 43 (75.0%)
Trials by Status
unknown125%
completed375%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_1
Pharmacokinetic Study of ASP1517 With Kremezin®
NCT02693613
completedphase_4
Effect of Replacement Volume of Haemodiafiltration and AST-120 on Toxins, Oxidative Stress and MicroInflammation
NCT01458652
unknownphase_4
The Effects of AST-120 on Endothelial Dysfunction in Patients With Chronic Kidney Disease
NCT01157260
completedphase_4
Carbonaceous Oral Adsorbent's Effects on Progression of Chronic Kidney Disease
NCT00456859
Clinical Trials (4)
Showing 4 of 4 trials
NCT02693613Phase 1
Pharmacokinetic Study of ASP1517 With Kremezin®
NCT01458652Phase 4
Effect of Replacement Volume of Haemodiafiltration and AST-120 on Toxins, Oxidative Stress and MicroInflammation
NCT01157260Phase 4
The Effects of AST-120 on Endothelial Dysfunction in Patients With Chronic Kidney Disease
NCT00456859Phase 4
Carbonaceous Oral Adsorbent's Effects on Progression of Chronic Kidney Disease
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4